Targeting T cells in inflammatory bowel disease.

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• T cells are central to inflammatory bowel disease (IBD) pathogenesis.
• Numerous drugs targeting T cells have been investigated for IBD over 25 years.
• Understanding T cell modulation is crucial for IBD treatment.

Purpose of the Study:

• To review drugs targeting T cells in IBD patients.
• To analyze the efficacy of different T cell-targeting strategies.
• To provide an overview of therapeutic approaches modulating T cell activity in IBD.

Main Methods:

• Review of clinical trials and preclinical studies of T cell-targeting drugs in IBD.
• Categorization of drugs based on their mechanism of action (surface receptors, cytokines, CRAC channels, apoptosis induction).
• Analysis of drug efficacy in ulcerative colitis (UC) and Crohn's disease (CD).

Main Results:

• Anti-CD3, anti-CD4, and anti-CD25 antibodies generally showed limited efficacy in IBD.
• An anti-NKG2D antibody demonstrated clinical benefit in Crohn's disease patients, especially those new to biologics.
• Drugs targeting T cell-derived cytokines largely failed, except for ustekinumab.
• Cyclosporin A, azathioprine, and anti-TNF-α agents modulate T cell survival by inducing apoptosis.

Conclusions:

• T cell-targeted therapies for IBD present a complex landscape with varying outcomes.
• Specific targets like NKG2D show potential, warranting further investigation.
• Apoptosis induction remains a viable strategy, as seen with established IBD medications.